慢性乙型肝炎肝细胞癌预测模型的系统评价与外部验证
本研究通过系统评价和荟萃分析14个肝细胞癌预测模型,并在986例接受恩替卡韦治疗的慢性乙型肝炎患者多中心队列中外部验证。结果显示所有模型区分度可接受,REAL-B模型在外部验证中区分度和校准度最佳,3年和5年AUROC分别为0.76和0.75。
要点
- REAL-B模型在慢性乙型肝炎患者中预测肝细胞癌的区分度和校准度最佳。
- 多数模型校准性能报道不足,需加强校准评估。
- 外部验证队列中REAL-B模型3年Brier评分为0.066,校准良好。
核心结论
- 在系统评价的肝细胞癌预测模型中,REAL-B模型表现出最佳的区分度和校准度。
研究设计与样本
- 系统评价和荟萃分析,随后在986例接受恩替卡韦治疗的慢性乙型肝炎患者多中心独立队列中进行外部验证,中位随访4.7年。
主要发现
- 共纳入14个模型,涉及123,885例患者和5,452例肝细胞癌病例。
- 汇总3年AUROC从0.70(REACH-B,95%CI 0.63-0.76)到0.83(REAL-B,95%CI 0.78-0.87)。
- 汇总5年AUROC从0.68(REACH-B,95%CI 0.64-0.73)到0.81(REAL-B,95%CI 0.77-0.85)。
- 汇总10年AUROC从0.70(PAGE-B,95%CI 0.58-0.80)到0.81(REAL-B,95%CI 0.78-0.84;AASL-HCC,95%CI 0.77-0.86)。
- 外部验证队列中REAL-B模型3年和5年AUROC分别为0.76(95%CI 0.69-0.83)和0.75(95%CI 0.70-0.81),3年Brier评分0.066。
临床怎么用
- 在慢性乙型肝炎患者肝细胞癌风险预测中,可优先考虑REAL-B模型。
局限性
- 大多数研究对校准性能报道不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The aim of our study was to characterize the performance of hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B (CHB) patients through meta-analysis followed by external validation. METHODS: We performed a systematic review and meta-analysis of current literature, followed by external validation in independent multi-center cohort with 986 patients with CHB undergoing entecavir treatment (median follow-up: 4.7 years). Model performance to predict HCC within 3, 5, 7, and 10 years was assessed using area under receiver operating characteristic curve (AUROC) and calibration index. Subgroup analysis were conducted by treatment status, cirrhotic, race and baseline alanine aminotransferase. RESULTS: We identified 14 models with 123,885 patients (5,452 HCC cases), with REACH-B, CU-HCC, GAG-HCC, PAGE-B and mPAGE-B models being broadly externally validated. Discrimination was generally acceptable for all models, with pooled AUC ranging from 0.70 (95% CI, 0.63-0.76 for REACH-B) to 0.83 (95% CI, 0.78-0.87 for REAL-B) for 3-year, 0.68 (95% CI, 0.64-0.73 for REACH-B) to 0.81 (95% CI, 0.77-0.85 for REAL-B) for 5-year and 0.70 (95% CI, 0.58-0.80 for PAGE-B) to 0.81 (95% CI, 0.78-0.84 for REAL-B and 0.77-0.86 for AASL-HCC) for 10-year prediction. However, calibration performance was poorly reported in most studies. In external validation cohort, REAL-B showed highest discrimination with 0.76 (95% CI, 0.69-0.83) and 0.75 (95% CI, 0.70-0.81) for 3 and 5-year prediction. The REAL-B model was also well calibrated in the external validation cohort (3-year Brier score 0.066). Results were consistent in subgroup analyses. CONCLUSIONS: In a systematic review of available HCC models, the REAL-B model exhibited best discrimination and calibration.
引用
- Wu S, Zeng N, Sun F, et al. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin Gastroenterol Hepatol. 2021. PMID: 33667678. doi:10.1016/j.cgh.2021.02.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。